https://www.cnbc.com/2018/09/10/alivecor-gets-fda-breakthrough-status-for-bloodless-hyperkalemia-test.html

AliveCor, a Silicon Valley start-up that develops technology to monitor people's heart health, on Monday received "breakthrough device" designation from the U.S. Food and Drug Administration for developing a new way to detect high blood potassium levels without requiring any blood.

AliveCor worked with doctors at the Mayo Clinic, which is also an investor in the company, to develop a new technology that looks for a dangerous condition called hyperkalemia without requiring any blood from the patient. It instead looks for patterns in electrocardiograms (ECGs), which are essentially recordings of the electrical signals of the heart.